Andere talen ObsEva SA

Aandelen

slotkoers Swiss Exchange Andere beurzen 00:00:00 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,006 ^CHF	+36,36%		+20,00%	-83,15%

03/04	ObsEva schrapt notering van de SIX Swiss Exchange	MT
20/03	ObsEva SA kondigt aan de activiteiten af te bouwen	CI

ObsEva to Delist from the SIX Swiss Exchange	03/04
ObsEva SA Announces to Wind-Down the Operations	20/03
ObsEva SA Announces Catarina Edfjäll to Step Down from the Board	20/03
ObsEva to Wind Down, Flags SIX Swiss Delisting	28/02
ObsEva Secures Temporary Moratorium Against Creditors	31/01
ObsEva to File for Moratorium in Geneva, Switzerland	30/11
ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals	30/11
ObsEva to Return Global Rights on Ebopiprant to Xoma	30-10-23
Organon Returns Ebopiprant to XOMA	27-10-23
ObsEva Net Loss Narrows in H1	27-09-23
ObsEva SA Reports Earnings Results for the Half Year Ended June 30, 2023	27-09-23
ObsEva Terminates Licensing Deal with Yuyuan BioScience for Oral Oxytocin Receptor	13-07-23
ObsEva Recovers Full Worldwide Rights on Nolasiban	13-07-23
ObsEva SA Announces Termination of Its Sub-Licensing Agreement with Yuyuan Bioscience	13-07-23
SIX Group Makes Index Adjustments Following Review	12-07-23
Morning Briefing - Markt Schweiz	02-05-23
Switzerland's ObsEva Appoints Permanent CEO	02-05-23
Obseva ernennt Fabien de Ladonchamps zum CEO	02-05-23
Aktien Schweiz Schluss: Der Freitag im Plus, die Woche im Minus	28-04-23
ObsEva SA announced that it expects to receive CHF 1.54 million in funding from ObsEva USA Inc.	08-12-22

Geen resultaten voor deze zoekopdracht